

Cleveland Clinic Laboratories

Fluorescence *In Situ* Hybridization (FISH) for B-Cell Chronic Lymphocytic Leukemia

Background Information

B-cell chronic lymphocytic leukemia (B-CLL) is a neoplasm of small B lymphocytes that involves the peripheral blood, bone marrow, and, in some patients, the lymph nodes. Most patients with B-CLL are older than 50 years of age at diagnosis, and most cases will follow an indolent clinical course.

In recent years, researchers have described chromosomal abnormalities in B-CLL that are correlated with prognosis and resistance to fludarabine. 1-3 Deletions of chromosome 17p involving the *TP53* locus have been identified in approximately 10% of B-CLL cases and are associated with an adverse prognosis. Similarly, deletions of chromosome 11q involving the *ATM* gene are reported in approximately 20% of B-CLL cases and likewise are associated with poor outcomes. In contrast, cases of B-CLL with deletions of chromosome 13q as a sole abnormality, detected in approximately 40% of cases, are associated with a favorable prognosis. Trisomy of chromosome 12 has been identified in approximately 10% of B-CLL and is associated with atypical morphologic features and an intermediate prognosis.

Interphase fluorescent *in situ* hybridization (FISH) is superior to metaphase cytogenetic studies for detecting these chromosomal abnormalities due to the low proliferative rate of B-CLL cells in culture.^{2,4}

Clinical Indications

Cleveland Clinic Laboratories offers FISH analysis for abnormalities of chromosomes 17p, 11q, 13q, and trisomy 12 to assist in the clinical evaluation of patients with B-CLL. Peripheral blood and bone marrow specimens involved by B-CLL are suitable for analysis.

Interpretation

Cases are classified as positive for del(11q), del(13q), or trisomy 12 when the corresponding abnormal signal pattern is observed in >10% of nuclei.

Cases are classified as positive for 17p deletion when loss of the 17p signal is detected in >15% of nuclei.

Limitations of the Assay

False negative results may occur if the neoplastic cells represent <15% (for 17p deletions) or <10% (for all other abnormalities) of the total cellularity in the sample analyzed.

This assay should be employed only in cases with an established diagnosis of B-CLL. The abnormalities identified by the test are not specific to B-CLL.

FISH studies do not exclude the presence of other chromosomal abnormalities that also may influence the prognosis of B-CLL.

Methodology

FISH analysis is performed on gravity preparations of peripheral blood or bone marrow samples. Cells are hybridized with a set of five probes described below (Vysis, Inc., Downer's Grove, III.). Probes are combined into two probe mixtures, each performed on a separate slide. 100 cells are evaluated for each probe.

Probe Set 1:

• Del(17p):

The LSI p53 (17p13.1) probe is a \sim 145 kb sequence labeled in Spectrum Orange.

Del(11q23):

The LSI ATM probe is a \sim 500 kb probe that encompasses the entire ATM locus at 11q22.3 and is labeled in Spectrum Green.

Probe Set 2:

Del(13q):

Abnormalities of chromosome 13q are detected using two probes to this region: The LSI D13S319 probe is a \sim 130 kb sequence that hybridizes to chromosome 13q14.3 and is labeled in Spectrum Orange.

The LSI 13q34 probe is a \sim 550 kb probe to the 13q34 region and is labeled in Spectrum Aqua.

• CEP12:

The CEP12 probe hybridizes to the centromeric region of chromosome 12 and is labeled in Spectrum Green.



Cleveland Clinic Laboratories

References

- Dohner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, Döhner K, Bentz. M, Lichter, P. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343:1910-1916.
- Shanafelt TD, Geyer SM, and Kay NE. Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. *Blood*. 2004;103:1202-1210.
- Stilgenbauer S, Bullinger L, Lichter P, Dohner H., German CLL Study Group (GCLLSG). Chronic lymphocytic leukemia. Genetics of chronic lymphocytic leukemia: genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course. *Leukemia*. 2002;16:993-1007.
- 4. Stilgenbauer S, Lichter P, Dohner H. Genetic features of B-cell chronic lymphocytic leukemia. *Rev Clin Exp Hematol.* 2000;4:48-72.

Test Overview

Test Name	FISH for B-CLL
Reference Range	Disomic for each probe
Specimen Requirements	8 mL of whole blood in two lavender (EDTA) 4 mL tubes OR bone marrow in EDTA
Test Ordering Information	CLLFSH
CPT Code	88368 (x5)

Technical Information Contacts:

Christine Dziekan, MT(ASCP) 216.444.8444 dziekac@ccf.org Wendy Nedlik, MT(ASCP) 216.444.8410 nedlikw@ccf.org

Scientific Information Contact:

James R. Cook, MD, PhD 216.444.4435 cookj2@ccf.org